Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Ovid Therapeutics (NASDAQ:OVID) in the last three months. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. The 12-month price targets, analyzed by analysts, offer insights with an average target of $3.03, a high estimate of $5.00, and a low estimate of $1.20. Highlighting a 48.9% decrease, the current average has fallen f…